JP2002128703A - Crude drug blended solubilized liquid composition - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a crude drug extract blended solubilized liquid composition being stable, not depending on its pH and a temperature. SOLUTION: This crude drug blended solubilized liquid composition is provided by blending a crude drug extract, a polyglycerol fatty acid ester, a polyoxyethylene-based nonionic surfactant and an oil component, and having that the blended amount of the polyoxyethylene-based non-ionic surfactant is 1/6-1 pt.mass based on the 1 pt.mass of the polyglycerol fatty acid ester.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

TECHNICAL FIELD The present invention relates to a solubilized liquid composition containing a crude drug extract and preventing the precipitation of polyglycerin fatty acid ester as a solubilizing agent.

[0002]

2. Description of the Related Art In recent years, crude drug extracts have been widely incorporated into liquid compositions such as drinks for the purpose of recovery from fatigue and the like. The herbal extract contains a wide variety of components, but some of them are poorly water-soluble. Therefore, in order to dissolve it in the liquid composition, a nonionic surfactant or the like as a solubilizing agent is required. Above all, polyoxyethylene hydrogenated castor oil is widely used as a solubilizing agent for crude drug extracts because of its excellent solubilizing power.

[0003] However, polyoxyethylene hydrogenated castor oil has the property of decomposing in the acidic or alkaline region and producing precipitates and suspended matters over time. Therefore, when polyoxyethylene hydrogenated castor oil is used as the solubilizer,
It was necessary to set the pH of the liquid composition to 4.5 or more (see Japanese Patent Publication No. 7-76474).

[0004] On the other hand, beverages are required from the viewpoints of preservability, flavor and the like.
It is desirable to set the pH to 4.5 or less, and it has been desired to develop a solubilization system that is stable even at a low pH.

[0005]

An object of the present invention is to provide a solubilized liquid composition containing a crude drug extract that is stable even at a low pH.

[0006]

In order to solve these problems, the present inventors have developed polyglycerol fatty acid esters which are excellent in acid resistance, salt resistance and heat resistance and are used as emulsifiers suitable for a wide range of applications. I paid attention. That is, it was confirmed that a stable crude drug extract-containing solubilized liquid composition can be prepared even at a low pH by using polyglycerin fatty acid ester as a solubilizing agent.

However, when the stability of the solubilized liquid composition over time was examined, it was found that precipitation and the like caused by the polyglycerol fatty acid ester occurred at low temperatures.

Therefore, the present inventors further studied and found that a liquid composition containing a crude drug extract containing polyglycerin fatty acid ester as a solubilizing agent contained an oil component such as soybean oil and a certain amount of polyoxyethylene-cured castor. It has been found that by adding oil, precipitation or the like at a low temperature can be prevented.

The present invention, which has been completed on the basis of such findings, comprises a crude drug extract, a polyglycerin fatty acid ester, a polyoxyethylene-based nonionic surfactant and an oil component, and a polyoxyethylene-based nonionic surfactant. The solubilized liquid composition is used in an amount of 1/6 to 1 part by mass per 1 part by mass of the polyglycerin fatty acid ester.

The form of the crude drug extract in the present invention is a dry powder of a crude drug, an extracted extract, a fluid extract and the like. Herbal medicines include carrots, horses, oaks, oaks, liquorice, squirrels, chimps, junipers, sanyakus, bakuryo, shukusha, jiou, touki, kukushi, kashuu, ryugannik, peonies, senkyu, kujuyu, jashoushi, toshikushi, skull , Silkworm, eucalypt, kaiba, onji,
Examples include Yokuinin, Sanshuyu, Gomeshi, Shokyo, Psycho, Keihi, Hampi, Muirapuama, Bakumondou, Gooh, Joteishi and the like.

The polyglycerin fatty acid ester in the present invention includes decaglycerin monomyristate, hexaglycerin monomyristate, decaglycerin monolaurate, hexaglycerin monolaurate, decaglycerin monostearate, hexaglycerin monostearate. ester,
Preferred are decaglycene monocaprylate, decaglycerin monooleate, hexaglycerin monooleate, decaglycerin monolinolenate and the like, and one or more of these may be blended. Among them, decaglycerin monomyristate, decaglycerin monostearate, and decaglycerin monolaurate are particularly preferred.

The amount of the polyglycerol fatty acid ester is 0.01 to 20 parts by mass, preferably 0.01 to 20 parts by mass, per 1 part by mass of the crude drug extract in terms of the crude drug.
2 parts by mass.

Examples of the polyoxyethylene-based nonionic surfactant in the present invention include polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, polyethylene glycol fatty acid ester, and polyoxyethylene glycerin fatty acid ester. , Polyoxyethylene hydrogenated castor oil is preferred.

The amount of the polyoxyethylene-based nonionic surfactant is 1/6 to 1 part by mass, and 1/5 to 1 part by mass, relative to 1 part by mass of the polyglycerol fatty acid ester.
One part by weight is preferred.

The oil component in the present invention includes vitamin E, derivatives of vitamin E, vitamin A, vitamin D, vitamin K, γ-oryzanol, soybean oil, and medium-chain triglyceride fatty acids such as triglyceride and γ-linolenic acid. Esters are mentioned.

The amount of the oil component is 0.01 to 1 part by mass, preferably 0.05 to 1 part by mass, per 1 part by mass of the polyglycerin fatty acid ester.

In the present invention, high-molecular substances such as polyvinylpyrrolidone, polyoxyethylene polyoxypropylene glycol, and polyvinyl alcohol can be blended for the purpose of suppressing precipitation caused by the crude drug extract. Among these, polyvinylpyrrolidone and polyoxyethylene polyoxypropylene glycol are preferred.

[0018]

DESCRIPTION OF THE PREFERRED EMBODIMENTS In the solubilized liquid composition of the present invention, it is effective to use a water-soluble polyhydric alcohol such as glycerin, diglycerin or polyglycerin as a solubilizing agent.

The pH of the solubilized liquid composition of the present invention is not particularly limited, and is characterized by not causing precipitation or the like even at a low pH. , PH 2.5-7, preferably 3-5.

The solubilized liquid composition of the present invention includes lactose, sucrose, fructose, glucose, sorbitol, maltitol, erythritol, xylitol, trehalose,
Stevia and the like can be blended as a sweetener or energy source.

In addition, vitamins, minerals, amino acids and salts thereof, royal jelly, caffeine, sodium chondroitin sulfate, etc., which are not oil components, can be blended as long as the effects of the present invention are not impaired.

Further, if necessary, other known additives,
For example, carriers commonly used in the preparation technology such as antioxidants, coloring agents, flavors, flavoring agents, solubilizers, preservatives, and pH adjusters can be blended. It can be an oral preparation and a beverage.

[0023]

The present invention will be described below in more detail with reference to Test Examples and Examples.

Test Examples Various surfactants, glycerin and soybean oil listed in Tables 1 and 2 were heated and mixed at 80 ° C., and then dissolved in hot water at 80 ° C. 0.3 w / v% of polyvinylpyrrolidone, 0.6 w / v% of muirapuama extract (equivalent to crude drug) and 1.0 w / v% of citric acid were added to each of these aqueous solutions, and pH was adjusted with a 1 mol / L sodium hydroxide solution. 3.
Adjusted to 0, 4.0, 4.6 and 5.0. These were filled in glass bottles, capped, and used as test solutions 1 to 5 and control solutions 1 to 4.

The test examples and the control solution were stored in a thermostat at 5 ° C. and 65 ° C. for 2 weeks, and the precipitates and suspended matters in the inner solution were visually observed. Table 3 shows the results. In addition,
The degree of precipitation and suspended matter was determined according to the following criteria.

Criteria for observation of sediment and suspended matter Neither sediment and suspended matter:-Presence of a small amount of sediment and suspended matter: + Significant sediment and suspended matter: ++

[0027]

[Table 1]

[Table 2]

[Table 3]

In the following examples, the values in parentheses are values (mg) converted to the crude drug. (Example 1) Peony extract 30 mg (120) Carrot extract 90 mg (600) Forsythia extract 0.3 mL (300) Licorice extract 50 mg (200) Jiao extract 300 mg (600) Tokyu extract 0.4 mL (400) Loquat tincture 1 0.08 mL (300) Epimedium extract 100 mg (1000) Ginger tincture 0.6 mL (120) Cauliflower extract 0.3 mL (300) Yokininryu extract 0.6 mL (600) Hampitinki 1.25 mL (250) Bukuro extract 9.6 mg (300) Taisounan extract 70mg (230) Muirapuama extract 15mg (300) Oyster lily extract 0.6mL (600) Kokushiryu extract 0.3mL (300) Psycholy Extract 0.15 mL (150) VB1 10 mg VB2 5 mg VB6 5 mg Caffeine 50 mg Taurine 500 mg Polyoxyethylene hydrogenated castor oil 60 100 mg Decaglycerin monomyristate 75 mg Decaglycerin monostearate 75 mg Glycerin 200 mg Soybean oil 30 mg White sugar 30 mg Polyvinyl pyrolipid Xylitol 4000mg Citric acid Appropriate amount DL-Sodium malate 200mg Propyl parahydroxybenzoate 3.3mg Butyl paraoxybenzoate 3.3mg Sodium benzoate 30mg Mixed fruit flavor 50mg The above components were stirred and dissolved in purified water, and the pH was 4.5. To obtain a total amount of 50 mL of the oral solution.

(Example 2) Carrot extract 90 mg (600) Onji extract 15 mg (150) Calyx tincture 500 mg (100) Licorice extract 50 mg (200) Jashoushi extract 600 mg (300) Geo extract 300 mg (600) Toshishi extract 33 mg (300) Cistanche salsa extract 151.6 mg (500) Ogi-ryu extract 0.6 mL (600) Calycium rhizome extract 0.3 mL (300) Gomi-shiru extract 0.3 mL (300) Sanshu-ryu extract 0.5 mL (500) Sanya-kryu extract 0 0.3 mL (300) Eucalyptus extract 0.4 mL (400) Eucommia extract 0.3 mL (300) Lingering tincture 1.08 mL (300) Epimedium extract 100 mg (1000) C Pitting tin 1.5 mL (300) Bulky extract 9.6 mg (300) Eucalyptus magnolia extract 0.3 mL (300) Muirapuama extract 17.5 mg (350) VB2 5 mg VB6 5 mg Caffeine 50 mg Taurine 500 mg Polyoxyethylene hydrogenated castor oil 60 100 mg Deca Glycerin monomyristate 200 mg Glycerin 2000 mg Soybean oil 20 mg Polyoxyethylene polyoxypropylphenol glycol 250 mg Trehalose 5000 mg D-sorbitol 4000 mg Stevia extract 5 mg Citric acid Sodium citrate 200 mg Sodium citrate sodium citrate 200 mg Mixed fruit flavor 5 mg The components of the dissolved with stirring in purified water, the pH was adjusted to 3.0 to obtain a oral liquid preparation of the total amount 50 mL.

[0030]

According to the present invention, it has been found that a solubilized liquid composition containing a crude drug extract which is stable even when stored for a long time regardless of pH or temperature can be provided.

 ──────────────────────────────────────────────────続 き Continued on the front page F term (reference) 4C076 AA12 DD38 DD41 DD43 DD45 DD46 DD67 EE03 EE16 EE23 EE51 EE53 FF15 4C088 AB12 CA09 CA28

Claims (4)

[Claims] 1. A crude drug extract, a polyglycerin fatty acid ester, a polyoxyethylene nonionic surfactant and an oil component are blended, and the blending amount of the polyoxyethylene nonionic surfactant is polyglycerin fatty acid ester. 1
A solubilized liquid composition which is 1/6 to 1 part by mass with respect to parts by mass. 2. The amount of the polyglycerin fatty acid ester to be added is 0.1 to 1 part by mass of a crude drug extract converted to a crude drug.
The solubilized liquid composition according to claim 1, wherein the amount is from 01 to 20 parts by mass. 3. The polyoxyethylene-based nonionic surfactant is a polyoxyethylene hydrogenated castor oil.
A solubilized liquid composition as described. 4. The solubilized liquid composition according to claim 1, further comprising polyvinylpyrrolidone or polyoxyethylene polyoxypropylene glycol.